Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06657105 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate the Pharmacokinetics of Ethinyl Estradiol and Levonorgestrel When Given Alone and in Combination With Baxdrostat in Healthy Females of Non-childbearing Potential
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT06657105 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 22 participants.
The verdict
NCT06657105, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
The main purpose of the study is to assess the effect of multiple doses of baxdrostat on the pharmacokinetics (PK) of a single dose of combined oral ethinyl estradiol (EE) and levonorgestrel (LNG). Safety and tolerability of baxdrostat will be assessed during the study.
Interventions
- DRUG Baxdrostat
- DRUG EE/LNG
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2024-11-01 |
| Est. Completion | 2025-02-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06657105
The ClinicalTrials.gov registry entry for NCT06657105 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Baxdrostat is the first listed.
NCT06657105 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06657105 about?
NCT06657105 is a clinical study titled "A Study to Investigate the Pharmacokinetics of Ethinyl Estradiol and Levonorgestrel When Given Alone and in Combination With Baxdrostat in Healthy Females of Non-childbearing Potential". The main purpose of the study is to assess the effect of multiple doses of baxdrostat on the pharmacokinetics (PK) of a single dose of combined oral ethinyl estradiol (EE) and levonorgestrel (LNG). Safety and tolerability of baxdrostat will be assessed during the study.
What is the current status of trial NCT06657105?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2024-11-01. Estimated completion is 2025-02-03.
What interventions are being tested in trial NCT06657105?
The interventions under investigation include: Baxdrostat (DRUG), EE/LNG (DRUG).
Who is sponsoring clinical trial NCT06657105?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.